Abstract
Chronic NK lymphoproliferative disease of large granular lymphocytes (LDGL) is characterized by the expansion of activated CD3−, CD16+ or CD56+ lymphocytes. The mechanism of survival of NK cells from LDGL patients is unknown but may be related to antigenic stimulation. There is currently no standard effective therapy for LDGL, and the disease is characteristically resistant to standard forms of chemotherapy. We found evidence of constitutive activation of extracellular-regulated kinase (ERK) in NK cells from 13/13 patients with NK-LDGL (one patient with aggressive and 12 patients with chronic disease). Ablation of ERK activity by inhibitors or a dominant-negative form of MEK, the upstream activator of ERK, reduced the survival of patient NK cells. Ras was also constitutively active in patient NK cells, and exposure of cells to the Ras inhibitor FTI2153 or to dominant-negative-Ras resulted not only in ERK inhibition but also in enhanced apoptosis in both the presence and absence of anti-Fas. Therefore, we conclude that a constitutively active Ras/MEK/ERK pathway contributes to the accumulation of NK cells in patients with NK-LDGL. These findings suggest that strategies to inhibit this signaling pathway may be useful for the treatment of the NK type of LDGL.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Alessi DR, Cuenda A, Cohen P, Dudley DT and Saltiel AR . (1995). J. Biol. Chem., 270, 27489–27494.
Chang L and Karin M . (2001). Nature, 410, 37–40.
Cohen JJ, Duke RC, Fadok VA and Sellins KS . (1992). Annu. Rev. Immunol., 10, 267–293.
Djeu JY, Jiang K and Wei S . (2002). Clin. Cancer Res., 8, 636–640.
Epling-Burnette PK, Liu JH, Catlett-Falcone R, Turkson J, Oshiro M, Kothapalli R, Li Y, Wang JM, Yang-Yen HF, Karras J, Jove R and Loughran Jr TP . (2001). J. Clin. Invest., 107, 351–362.
Epling-Burnette PK, Painter JS, Chaurasia P, Bai F, Wei S, Djeu JY and Loughran TP . (2004). Blood, 103, 3431–3439.
Ferlazzo G, Morandi B, D'Agostino A, Meazza R, Melioli G, Moretta A and Moretta L . (2003). Eur. J. Immunol., 33, 306–313.
He T, Stepulak A, Holmstrom TH, Omary MB and Eriksson JE . (2002). J. Biol. Chem., 277, 10767–10774.
Holmstrom TH, Schmitz I, Soderstrom TS, Poukkula M, Johnson VL, Chow SC, Krammer PH and Eriksson JE . (2000). EMBO J., 19, 5418–5428.
Husain Z, Alper CA, Yunis EJ and Dubey DP . (2002). Immunology, 106, 373–380.
Jiang K, Zhong B, Gilvary DL, Corliss BC, Hong-Geller E, Wei S and Djeu JY . (2000). Nat. Immunol., 1, 419–425.
Lamy T, Liu JH, Landowski TH, Dalton WS and Loughran Jr TP . (1998). Blood, 92, 4771–4777.
Lanier LL, Cwirla S, Federspiel N and Phillips JH . (1986). J. Exp. Med., 163, 209–214.
Lerner EC, Qian Y, Blaskovich MA, Fossum RD, Vogt A, Sun J, Cox AD, Der CJ, Hamilton AD and Sebti SM . (1995). J. Biol. Chem., 270, 26802–26806.
Lerner EC, Zhang TT, Knowles DB, Qian Y, Hamilton AD and Sebti SM . (1997). Oncogene., 15, 1283–1288.
Lima M, Almeida J, dos Anjos Teixeira M, Queiros ML, Justica B and Orfao A . (2002). Blood Cells Mol. Dis., 28, 181–190.
Li N, Batzer A, Daly R, Yajnik V, Skolnik E, Chardin P, Bar-Sagi D, Margolis B and Schlessinger J . (1993). Nature, 363, 85–88.
Loughran Jr TP . (1993). Blood, 82, 1–14.
Loughran Jr TP, Hadlock KG, Yang Q, Perzova R, Zambello R, Semenzato G, Foung SK and Poiesz BJ . (1997). Blood, 90, 1977–1981.
Loughran Jr TP, Kadin ME, Starkebaum G, Abkowitz JL, Clark EA, Disteche C, Lum LG and Slichter SJ . (1985). Ann. Intern. Med., 102, 169–175.
Loughran Jr TP, Sherman MP, Ruscetti FW, Frey S, Coyle T, Montagna RA, Jones B, Starkebaum G and Poiesz BJ . (1994). Leuk. Res., 18, 423–429.
McVicar DW and Burshtyn DN . (2001). Sci. STKE, 2001, RE1.
Miyawaki T, Uehara T, Nibu R, Tsuji T, Yachie A, Yonehara S and Taniguchi N . (1992). J. Immunol., 149, 3753–3758.
Montagna D, Moretta A, Marconi M, Mingrat G, Gasparoni A, Giarola M and Maccario R . (1992). Biol. Neonate, 62, 385–394.
Ohno T, Kanoh T, Arita Y, Fujii H, Kuribayashi K, Masuda T, Horiguchi Y, Taniwaki M, Nosaka T, Hatanaka M and Uchino I . (1988). Cancer, 62, 1918–1927.
Ortaldo JR, Mason AT and O'Shea JJ . (1995). J. Exp. Med., 181, 339–344.
Perzova RN, Loughran TP, Dube S, Ferrer J, Esteban E and Poiesz BJ . (2000). Br. J. Haematol., 109, 64–70.
Ritz J, Campen TJ, Schmidt RE, Royer HD, Hercend T, Hussey RE and Reinherz EL . (1985). Science, 228, 1540–1543.
Scheid MP, Schubert KM and Duronio V . (1999). J. Biol. Chem., 274, 31108–31113.
Semenzato G, Pandolfi F, Chisesi T, De Rossi G, Pizzolo G, Zambello R, Trentin L, Agostini C, Dini E, Vespignani M, Cafaro A, Pasqualetti D, Giubellino C, Migone N and Foa R . (1987). Cancer, 60, 2971–2978.
Soderstrom TS, Poukkula M, Holmstrom TH, Heiskanen KM and Eriksson JE . (2002). J. Immunol., 169, 2851–2860.
Sun J, Blaskovich MA, Knowles D, Qian Y, Ohkanda J, Bailey RD, Hamilton AD and Sebti SM . (1999). Cancer Res., 59, 4919–4926.
Takahashi A, Day NK, Luangwedchakarn V, Good RA and Haraguchi S . (2001). J. Immunol., 166, 6771–6775.
Taniwaki M, Tagawa S, Nishigaki H, Horiike S, Misawa S, Shimazaki C, Maekawa T, Fujii H, Kitani T and Abe T . (1990). Am. J. Hematol., 33, 32–38.
Tefferi A, Li CY, Witzig TE, Dhodapkar MV, Okuno SH and Phyliky RL . (1994). Blood, 84, 2721–2725.
Timonen T, Ortaldo JR and Herberman RB . (1981). J. Exp. Med., 153, 569–582.
Tran SE, Holmstrom TH, Ahonen M, Kahari VM and Eriksson JE . (2001). J. Biol. Chem., 276, 16484–16490.
Watanabe-Fukunaga R, Brannan CI, Copeland NG, Jenkins NA and Nagata S . (1992). Nature, 356, 314–317.
Wei S, Gamero AM, Liu JH, Daulton AA, Valkov NI, Trapani JA, Larner AC, Weber MJ and Djeu JY . (1998). J. Exp. Med., 187, 1753–1765.
Wei S, Gilvary DL, Corliss BC, Sebti S, Sun J, Straus DB, Leibson PJ, Trapani JA, Hamilton AD, Weber MJ and Djeu JY . (2000). J. Immunol., 165, 3811–3819.
Zingoni A, Palmieri G, Morrone S, Carretero M, Lopez-Botel M, Piccoli M, Frati L and Santoni A . (2000). Eur. J. Immunol., 30, 644–651.
Acknowledgements
This work was supported by the following grants: Veterans' Administration Hospital and National Institute of Health Grants AI056213, CA90633, CA83146, CA83947, and CA94872. We would like to thank the Flow Cytometry Core and Molecular Imaging Core Facilities at H Lee Moffitt Cancer Center for assistance with data analysis and preparation of this manuscript.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Epling-Burnette, P., Bai, F., Wei, S. et al. ERK couples chronic survival of NK cells to constitutively activated Ras in lymphoproliferative disease of granular lymphocytes (LDGL). Oncogene 23, 9220–9229 (2004). https://doi.org/10.1038/sj.onc.1208122
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1208122
Keywords
This article is cited by
-
miR-181a is a novel player in the STAT3-mediated survival network of TCRαβ+ CD8+ T large granular lymphocyte leukemia
Leukemia (2022)
-
T-cell large granular lymphocyte leukemia in solid organ transplant recipients: case series and review of the literature
International Journal of Hematology (2019)
-
Tipifarnib-mediated suppression of T-bet-dependent signaling pathways
Cancer Immunology, Immunotherapy (2012)
-
Boolean network simulations for life scientists
Source Code for Biology and Medicine (2008)
-
Oncogenic tyrosine kinase NPM/ALK induces activation of the MEK/ERK signaling pathway independently of c-Raf
Oncogene (2007)